Biotechnology and life sciences innovation
Dr. Bashar Al Noorachi built MATIC 3D printers so dental labs would not wait on imports. The Magic surgical Guide workflow, shown from ITEX Iraq to LEAP 2026, runs from dual-scan planning through RealGUIDE and a printed sleeve. Public hardware specs remain thin.
Sarat Investment aims to put $100 million into 20 biotechnology companies. That is a stated mandate, not a published first close. A 2025 Sarat Ventures vehicle had already flagged about $50 million for Saudi- and MENA-tied biotech.
The Oman Investment Authority has invested in Cambridge Innovation Capital and Oxford Science Enterprises, betting on world-class deep tech in quantum computing and life sciences, with an eye on transferring that knowledge home.
Reme-D, an Egyptian healthtech company building molecular diagnostic tests, has closed a $1.45 million Pre-Series A round led by Anara Impact Capital to expand manufacturing and its African footprint.
Isomorphic Labs raised $2.1 billion in a Series B round with MGX among its new investors. The Alphabet-backed AI drug discovery company is using the capital to scale its drug design engine and push its first compounds toward clinical trials.
Oman Investment Authority has invested in Neuralink as the brain-computer interface company accelerates human trials. By January 2026 the company had implanted devices in 21 patients with a target of 1000 procedures before year end.
Egypt based Nawah Scientific raises $23 million in a Series A round to expand its cloud laboratory infrastructure and scale life sciences research across new markets.
Wa’ed Ventures, Saudi Aramco’s venture capital arm, led a $10 million pre-Series A round in Kure Cells. The US biotech firm will establish a cell therapy R&D and manufacturing hub in Saudi Arabia, aligning with Vision 2030.
Abu Dhabi’s Hub71 launches Hub71+ Life Sciences to drive biotech and digital health innovation as MENA’s healthcare market nears USD 412 billion by 2032.